Tumor Infiltrating Cytotoxic CD8 T‑Cells Predict Clinical Outcome of Neuroblastoma in Children

Abstract

Context: Neuroblastoma is often infiltrated by inflammatory cells, particularly macrophages and T lymphocytes, but the significance of these cells remains unclear. One possible role of these inflammatory cells is that they represent a cell-mediated immune response against cancer. CD8+ lymphocytes are a known crucial component of cell-mediated immunity. The purpose of this study was to explore the prognostic value of tumor-infiltrating CD8+ cytotoxic lymphocytes in Neuroblastoma. Subjects and Methods:Tumor-infiltrating CD8+ lymphocytes were assessed by immunohistochemical staining of tumor tissue from 36 neuroblastoma from April 2008 to May 2015. The number of CD8+ T-cells was counted in tumor nest (intratumoral) and in the fibrovascular stroma of tumor (peritumoral), and their relationship with clinicopathologic outcome was determined. Results: The total number of CD8+ cells was inversely correlated with tumor histology grade (P < 0.001), vascular invasion (P < 0.001), capsular invasion (P < 0.002), calcification (P < 0.005), necrosis of tumor (P < 0.001), regional lymph nodes invasion (P < 0.003), distant metastasis (P < 0.003), stage (P < 0.003), and was positive correlated with N-myc oncogene presentation (P < 0.002) in neuroblastoma. However, there were no correlation between patient's age, sex, and size of tumor with infiltration of CD8+ cells (P < 0.097, P < 0.142, and P < 0.722, respectively). Conclusions: In this analysis, total CD8 T-cell count was a dependent prognostic factor in children. Total number and stromal CD8 lymphocytes were associated with better patient survival (P < 0.003 and P < 0.05, respectively) in children. These results suggest that tumor-infiltrating CD8 T lymphocytes have antitumor activity and influence the behavior of neuroblastoma and might be potentially be exploited in the treatment of neuroblastoma in children.

Keywords

Children - cytotoxic CD8 lymphocyte - neuroblastoma - outcome

Publikationsverlauf

Artikel online veröffentlicht:
23. Juni 2021

• References

• 1 Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF. et al.,(eds). SEER Cancer Statistics Review, 1975-2010, Section 29. Bethesda, MD: National Cancer Institute; 2013
• 2 Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL. Declining childhood and adolescent cancer mortality. Cancer 2014; 120: 2497-506
• 3 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF. et al., (eds). SEER Cancer Statistics Review, 1975-2012, Bethesda, MD: National Cancer Institute; 2014
• 4 Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48
• 5 Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007; 121: 1-14
• 6 Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM. et al. Cancer and inflammation: Promise for biologic therapy. J Immunother 2010; 33: 335-51
• 7 Facchetti P, Prigione I, Ghiotto F, Tasso P, Garaventa A, Pistoia V. et al. Functional and molecular characterization of tumour-infiltrating lymphocytes and clones thereof from a major-histocompatibility-complex-negative human tumour: Neuroblastoma. Cancer Immunol Immunother 1996; 42: 170-8
• 8 Carlson LM, De GeerA, Sveinbjørnsson B, Orrego A, Martinsson T, Kogner P. et al. The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes. Oncoimmunology 2013; 2: e23618
• 9 Martin RF, Beckwith JB. Lymphoid infiltrates in neuroblastomas: Their occurrence and prognostic significance. J Pediatr Surg 1968; 3: 161-4
• 10 Squire R, Fowler CL, Brooks SP, Rich GA, Cooney DR. The relationship of class I MHC antigen expression to stage IV-S disease and survival in neuroblastoma. J Pediatr Surg 1990; 25: 381-6
• 11 Valteau D, Scott V, Carcelain G, Hartmann O, Escudier B, Hercend T. et al. T-cell receptor repertoire in neuroblastoma patients. Cancer Res 1996; 56: 362-9
• 12 Mina M, Boldrini R, Citti A, Romania P, D'Alicandro V, De Ioris MK. et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology 2015; 4: e1019981
• 13 Fridman WH, Mlecnik B, Bindea G, Pagès F, Galon J. Immunosurveillance in human non-viral cancers. Curr Opin Immunol 2011; 23: 272-8
• 14 Martinet L, Garrido I, Filleron T, Le GuellecS, Bellard E, Fournie JJ. et al. Human solid tumors contain high endothelial venules: Association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res 2011; 71: 5678-87
• 15 Ladoire S, Arnould L, Mignot G, Apetoh L, Rébé C, Sarin YK. et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer 2011; 105: 366-71
• 16 Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH. et al. Chemokine-driven lymphocyte infiltration: An early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012; 61: 427-38
• 17 Lança T, Silva-Santos B. et al. The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology 2012; 1: 717-25
• 18 Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K. et al. Smaller neuroblastoma tumors in mice intratumorally treated with Hu14. 18-IL2 have more activated tumor-infiltrating lymphocytes and better outcome. Cancer Immunol Immunother 2013; 62: 1303-13
• 19 Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-21
• 20 Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol 2011; 21: 229-37
• 21 Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014; 257: 56-71
• 22 Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T. et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29: 610-8
• 23 Angevin E, Kremer F, Gaudin C, Hercend T, Triebel F. Analysis of T-cell immune response in renal cell carcinoma: Polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int J Cancer 1997; 72: 431-40
• 24 Elder DE, Guerry D, VanHorn M, Hurwitz S, Zehngebot L, Goldman LI. et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 1985; 56: 413-8
• 25 Mihm MCJr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74: 43-7
• 26 Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 2004; 101 Suppl 2: 14639-45
• 27 Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86: 1159-66
• 28 Stewart TH, Heppner GH. Immunological enhancement of breast cancer. Parasitology 1997; 115 Suppl: S141-53
• 29 Mina M, Boldrini R, Citti A, Romania P, D'Alicandro V, De Ioris MK. et al. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology 2015; 4: e1019981